Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
R&D Pipeline
4 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Aurobindo's 22 Drug Pipelines
20 July 2023
Aurobindo Pharma Ltd. is a pharmaceutical organization that was founded in 1986 and is based in Andhra Pradesh, India.
Advanced Tech.
5 min read
Boosting anti-PD-1 PD-L1 therapy by targeting YTHDF1
20 July 2023
YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity.
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of STADA Arzneimittel's 19 Drug Pipelines
20 July 2023
STADA Arzneimittel AG is a pharmaceutical organization that was founded in 1895 and is based in Hessen, Germany.
R&D Pipeline
3 min read
Top 50 Pharmaceutical Companies R&D Progress: An Overview of Jazz's 61 Drug Pipelines
20 July 2023
Jazz Pharmaceuticals Plc is a pharmaceutical company that was founded in 2003 and is headquartered in Dublin, Ireland.
Advanced Tech.
5 min read
Breaking Through the Blood-Brain Barrier: P-Selectin-Targeted Nanocarriers Promote Active Crossing
20 July 2023
Fucoidan-based nanocarriers can actively transport therapeutic cargo across tumor endothelium, allowing for targeted delivery to the tumor microenvironment. This approach holds immense potential to revolutionize therapeutic outcomes for diseases with an intact BBB, such as SHH-MB, and could usher in a new era of improved therapies for a multitude of brain diseases.
Advanced Tech.
6 min read
The Dual Boom of Bispecific Antibodies: Market and Drug Discovery Pipeline
18 July 2023
They have gained broad potential in preclinical and clinical investigations in a variety of tumor types following regulatory approval of newly developed technologies involving bispecific and multispecific antibodies.
Valuable Targets
10 min read
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
17 July 2023
the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.
Bio Sequence
4 min read
No sequence will be left unexplored with Patsnap Bio!
17 July 2023
In order to address the risk of missed detection brought by degenerate sequences, the Patsnap Engineering team utilizes its self-developed NLP, CV, entity recognition, anaphora resolution and other technologies to construct a deep learning model.
Hot Spotlight
5 min read
The GLP-1R plus strategy for curbing the obesity epidemic
14 July 2023
this approach brings new hope that we can finally address the growing concern of obesity worldwide.
Valuable Targets
5 min read
Cdc42 provides a new target for treating Alzheimer’s Disease
13 July 2023
the small G protein family member, Cdc42, plays an important role in the progression of Alzheimer's disease.
Drug Insights
4 min read
Discovery of a New Drug for Inflammatory and Autoimmune Diseases: TAK-279
12 July 2023
TAK-279, which is a highly selective inhibitor of TYK2 enzymatic activity.
Advanced Tech.
5 min read
Organoid-On-Chips: A Potential Game Changer for Clinical Studies
12 July 2023
HRS-1893 works through a special mechanism that inhibits myocardial excessive contraction and is intended for the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy.